Biologics

The company is working on growth levers, such as expanding biologics manufacturing in Bengaluru, investing in clinical capabilities for peptides, and foraying into clinical trials opportunity.

Biocon’s Rs 4,500 crore QIP to help retire debt, fuel new launches, says CEO Sidharth Mittal

Biocon’s debt profile has been under investor scrutiny after a strategic acquisition of Viatris Inc's biosimilars business for roughly $3.3 billion in 2022. This deal, while transformative for Biocon Biologics, had significantly increased the company's leverage.

Aurobindo Pharma's arm to invest around Rs 300 crore for biologics manufacturing facilities

Auro Vaccines is engaged in the business of developing and manufacturing vaccines biologicals.

Ideas For Profit | Gland Pharma trades at a discount to Syngene & Divi’s; Enough triggers to invest?

With the rising prevalence of chronic diseases and growth of biologics, MC Pro recommends holding Gland Pharma. Post the recent correction and downward adjustments in estimates, Gland Pharma is trading at 17x EV/EBITDA for FY24e. Here’s why it makes for a good investment bet.

Focus on growth, investments; capacity in Biologics a growth driver: Syngene Intl

EBITDA Margins around 31-33% with focus on growth and investments are good, said Jonathan Hunt, CEO of Syngene International.

New products, regulatory approvals to drive growth for Glenmark

The company is expecting strong growth in the current fiscal both from India and US. Major approvals are expected to drive growth for Glenmark, says Chairman and Managing Director Glenn Saldanha.

Biocon Q1 net up 17% at Rs 147 cr

The Bangalore-based firm had posted a net profit of Rs 126 crore during the same period of previous fiscal.

India's oncology mkt to touch Rs 3,831cr by 2017: Study

Among this chemotherapy recorded the highest market value of approximately Rs 700 crore in 2012. Oncology market in India is forecasted to grow to Rs 3,831 crore by 2017," a study by Frost & Sullivan said.